IgA Nephropathy Drug With Novel Mechanism Wins FDA Approval

MedPage Today) — The FDA granted accelerated approval to atrasentan (Vanrafia) for the reduction of proteinuria in adults with primary immunoglobulin A (IgA) nephropathy, maker Novartis announced late on Wednesday. The tablets are indicated…

About Author

Arden Kazmierczak

See author's posts

IgA Nephropathy Drug With Novel Mechanism Wins FDA Approval

About Author

Arden Kazmierczak

‘Zombie’ skin cells may be harmful or helpful, depending on their shapes

What to know about processed and ultra-processed food

Medical debt tied to higher likelihood of forgone mental health care

‘Zombie’ skin cells may be harmful or helpful, depending on their shapes

What to know about processed and ultra-processed food

Medical debt tied to higher likelihood of forgone mental health care

Survey reveals women may be experiencing perimenopause in their 40s

US Preventive Services Task Force recommends counseling to prevent perinatal depression

FDA outbreak investigations continue

Are Primary Care Visits Declining in the United States?

Rare ESWL Outcome: Liver Capsule Rupture Leads to Emergency

Do Ammonia Salts Pose a Health Risk for Hockey Players?

Extra Caution Needed for GLP-1s in Those With Chronic Issues

‘Zombie’ skin cells may be harmful or helpful, depending on their shapes

What to know about processed and ultra-processed food

Medical debt tied to higher likelihood of forgone mental health care

Survey reveals women may be experiencing perimenopause in their 40s

US Preventive Services Task Force recommends counseling to prevent perinatal depression

About PhaMed

Recent News

About Author

More Stories

You may have missed

About PhaMed

Recent News

Categories